Intratumoral Heterogeneity of the Epigenome

Cancer Cell

Volumn 29, Issue 4, 2016, Pages 440-451

  Mazor, Tali ^a   Pankov, Aleksandr ^a   Song, Jun S ^a,b,c   Costello, Joseph F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Illinois at Urbana Champaign   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

CELL FUNCTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLORECTAL CANCER; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENETIC HETEROGENEITY; GENOME ANALYSIS; HISTONE MODIFICATION; HUMAN; INTRATUMORAL HETEROGENEITY; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SINGLE CELL ANALYSIS; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR GENE; TUMOR SUPPRESSOR GENE; CANCER STEM CELL; CELL TRANSFORMATION; CHEMISTRY; CPG ISLAND; DISEASE COURSE; FORECASTING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; PROMOTER REGION;

CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; EPIGENOMICS; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; MUTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; PROMOTER REGIONS, GENETIC;

EID: 84962707515     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.03.009     Document Type: Review

References (132)

1. Aggerholm A., Guldberg P., Hokland M., Hokland P. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res. 1999, 59:436-441.
2. Alizadeh A.A., Aranda V., Bardelli A., Blanpain C., Bock C., Borowski C., Caldas C., Califano A., Doherty M., Elsner M., et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 2015, 21:846-853.
3. Alpar D., Barber L.J., Gerlinger M. Chapter 24. Genetic intratumor heterogeneity. Epigenetic Cancer Therapy 2015, 569-594. Elsevier Inc. S.G. Gray (Ed.).
4. Angermueller C., Clark S.J., Lee H.J., Macaulay I.C., Teng M.J., Hu T.X., Krueger F., Smallwood S.A., Ponting C.P., Voet T., et al. Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity. Nat. Methods 2016, 13:229-232.
5. Aryee M.J., Liu W., Engelmann J.C., Nuhn P., Gurel M., Haffner M.C., Esopi D., Irizarry R.A., Getzenberg R.H., Nelson W.G., et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl Med. 2013, 5:169ra110.
6. Aumann S., Abdel-Wahab O. Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochem. Biophys. Res. Commun. 2014, 455:24-34.
7. Bochtler T., Stölzel F., Heilig C.E., Kunz C., Mohr B., Jauch A., Janssen J.W.G., Kramer M., Benner A., Bornhäuser M., et al. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J. Clin. Oncol. 2013, 31:3898-3905.
8. Brena R.M., Costello J.F. Genome-epigenome interactions in cancer. Hum. Mol. Genet. 2007, 16:R96-R105.
9. Brocks D., Assenov Y., Minner S., Bogatyrova O., Simon R., Koop C., Oakes C., Zucknick M., Lipka D.B., Weischenfeldt J., et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 2014, 8:798-806.
10. Buenrostro J.D., Wu B., Litzenburger U.M., Ruff D., Gonzales M.L., Snyder M.P., Chang H.Y., Greenleaf W.J. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 2015, 523:486-490.
11. Cahill N., Bergh A.-C., Kanduri M., Göransson-Kultima H., Mansouri L., Isaksson A., Ryan F., Smedby K.E., Juliusson G., Sundström C., et al. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 2013, 27:150-158.
12. Cara S., Tannock I.F. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann. Oncol. 2001, 12:23-27.
13. Christians A., Hartmann C., Benner A., Meyer J., von Deimling A., Weller M., Wick W., Weiler M. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One 2012, 7:e33449.
14. Cooper C.S., Eeles R., Wedge D.C., Van Loo P., Gundem G., Alexandrov L.B., Kremeyer B., Butler A., Lynch A.G., Camacho N., et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet. 2015, 47:367-372.
15. Costello J.F., Futscher B.W., Kroes R.A., Pieper R.O. Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines. Mol. Cell Biol. 1994, 14:6515-6521.
16. Costello J.F., Berger M.S., Huang H.S., Cavenee W.K. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 1996, 56:2405-2410.
17. Cusanovich D.A., Daza R., Adey A., Pliner H.A., Christiansen L., Gunderson K.L., Steemers F.J., Trapnell C., Shendure J. Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing. Science 2015, 348:910-914.
18. De Carvalho D.D., Sharma S., You J.S., Su S.F., Taberlay P.C., Kelly T.K., Yang X., Liang G., Jones P.A. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012, 21:655-667.
19. De S., Shaknovich R., Riester M., Elemento O., Geng H., Kormaksson M., Jiang Y., Woolcock B., Johnson N., Polo J.M., et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. Plos Genet. 2013, 9:e1003137.
20. Ding L., Ley T.J., Larson D.E., Miller C.A., Koboldt D.C., Welch J.S., Ritchey J.K., Young M.A., Lamprecht T., McLellan M.D., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
21. Ding L., Wendl M.C., McMichael J.F., Raphael B.J. Expanding the computational toolbox for mining cancer genomes. Nat. Rev. Genet. 2014, 15:556-570.
22. Dunn J., Baborie A., Alam F., Joyce K., Moxham M., Sibson R., Crooks D., Husband D., Shenoy A., Brodbelt A., et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br. J. Cancer 2009, 101:124-131.
23. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., Danenberg P.V., Laird P.W. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28:E32.
24. Eads C.A., Lord R.V., Kurumboor S.K., Wickramasinghe K., Skinner M.L., Long T.I., Peters J.H., DeMeester T.R., Danenberg K.D., Danenberg P.V., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000, 60:5021-5026.
25. Elliott G., Hong C., Xing X., Zhou X., Li D., Coarfa C., Bell R.J., Maire C.L., Ligon K.L., Sigaroudinia M., et al. Intermediate DNA methylation is a conserved signature of genome regulation. Nat. Commun. 2015, 6:6363.
26. Fang F., Munck J., Tang J., Taverna P., Wang Y., Miller D.F., Pilrose J., Choy G., Azab M., Pawelczak K.S., et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin. Cancer Res. 2014, 20:6504-6516.
27. Farlik M., Sheffield N.C., Nuzzo A., Datlinger P., Schönegger A., Klughammer J., Bock C. Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics. Cell Rep. 2015, 10:1386-1397.
28. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
29. Fiegl H., Millinger S., Goebel G., Muller-Holzner E., Marth C., Laird P.W., Widschwendter M. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res. 2006, 66:29-33.
30. Furnari F.B., Cloughesy T.F., Cavenee W.K., Mischel P.S. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat. Rev. Cancer 2015, 15:302-310.
31. Gama-Sosa M.A., Slagel V.A., Trewyn R.W., Oxenhandler R., Kuo K.C., Gehrke C.W., Ehrlich M. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983, 11:6883-6894.
32. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
33. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
34. Gerlinger M., Horswell S., Larkin J., Rowan A.J., Salm M.P., Varela I., Fisher R., McGranahan N., Matthews N., Santos C.R., et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 2014, 46:225-233.
35. Gilbert M.R., Wang M., Aldape K.D., Stupp R., Hegi M.E., Jaeckle K.A., Armstrong T.S., Wefel J.S., Won M., Blumenthal D.T., et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J. Clin. Oncol. 2013, 31:4085-4091.
36. Goelz S.E., Vogelstein B., Hamilton S.R., Feinberg A.P. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985, 228:187-190.
37. Graff J.R., Herman J.G., Lapidus R.G., Chopra H., Xu R., Jarrard D.F., Isaacs W.B., Pitha P.M., Davidson N.E., Baylin S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995, 55:5195-5199.
38. Graff J.R., Gabrielson E., Fujii H., Baylin S.B., Herman J.G. Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol. Chem. 2000, 275:2727-2732.
39. Grasbon-Frodl E.M., Kreth F.W., Ruiter M., Schnell O., Bise K., Felsberg J., Reifenberger G., Tonn J.-C., Kretzschmar H.A. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int. J. Cancer 2007, 121:2458-2464.
40. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
41. Greger V., Debus N., Lohmann D., Höpping W., Passarge E., Horsthemke B. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma. Hum. Genet. 1994, 94:491-496.
42. Gundem G., Van Loo P., Kremeyer B., Alexandrov L.B., Tubio J.M., Papaemmanuil E., Brewer D.S., Kallio H.M., Hognas G., Annala M., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015, 520:353-357.
43. Guo H., Zhu P., Guo F., Li X., Wu X., Fan X., Wen L., Tang F. Profiling DNA methylome landscapes of mammalian cells with single-cell reduced-representation bisulfite sequencing. Nat. Protoc. 2015, 10:645-659.
44. Gupta P.B., Fillmore C.M., Jiang G., Shapira S.D., Tao K., Kuperwasser C., Lander E.S. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
45. Hamilton M.G., Roldan G., Magliocco A., McIntyre J.B., Parney I., Easaw J.C. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J. Neurooncol. 2011, 102:255-260.
46. Hanson J.A., Gillespie J.W., Grover A., Tangrea M.A., Chuaqui R.F., Emmert-Buck M.R., Tangrea J.A., Libutti S.K., Linehan W.M., Woodson K.G. Gene promoter methylation in prostate tumor-associated stromal cells. J. Natl. Cancer Inst. 2006, 98:255-261.
47. Hegi M.E., Diserens A.-C., Gorlia T., Hamou M.-F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
48. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., Samid D., Duan D.S., Gnarra J.R., Linehan W.M. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 1994, 91:9700-9704.
49. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996, 93:9821-9826.
50. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.P., Markowitz S., Willson J.K., Hamilton S.R., Kinzler K.W., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 1998, 95:6870-6875.
51. Hinoue T., Weisenberger D.J., Pan F., Campan M., Kim M., Young J., Whitehall V.L., Leggett B.A., Laird P.W. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 2009, 4:e8357.
52. Hogan L.E., Meyer J.A., Yang J., Wang J., Wong N., Yang W., Condos G., Hunger S.P., Raetz E., Saffery R., et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 2011, 118:5218-5226.
53. Hon G.C., Rajagopal N., Shen Y., McCleary D.F., Yue F., Dang M.D., Ren B. Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. Nat. Genet. 2013, 45:1198-1206.
54. Hou Y., Song L., Zhu P., Zhang B., Tao Y., Xu X., Li F., Wu K., Liang J., Shao D., et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012, 148:873-885.
55. Johnson B.E., Mazor T., Hong C., Barnes M., Aihara K., McLean C.Y., Fouse S.D., Yamamoto S., Ueda H., Tatsuno K., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014, 343:189-193.
56. Ju H.X., An B., Okamoto Y., Shinjo K., Kanemitsu Y., Komori K., Hirai T., Shimizu Y., Sano T., Sawaki A., et al. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am. J. Pathol. 2011, 178:1835-1846.
57. Kane M.F., Loda M., Gaida G.M., Lipman J., Mishra R., Goldman H., Jessup J.M., Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997, 57:808-811.
58. Kaufman, C.K., Mosimann, C., Fan, Z.P., Yang, S., Thomas, A.J., Ablain, J.,Tan J.L., Fogley R.D., Van Rooijen E., Hagedorn E.J., Ciarlo C., White R.M., Matos D.A., Puller A.-C., Santoriello C., Liao E.C., Young R.A., Zon L.I.A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science, 351(6272), 2016.
59. Klump B., Hsieh C.J., Holzmann K., Gregor M. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998, 115:1381-1386.
60. Koestler D.C., Christensen B., Karagas M.R., Marsit C.J., Langevin S.M., Kelsey K.T., Wiencke J.K., Houseman E.A. Blood-based profiles of DNA methylation predict the underlying distribution of cell types: a validation analysis. Epigenetics 2013, 8:816-826.
61. Korshunova Y., Maloney R.K., Lakey N., Citek R.W., Bacher B., Budiman A., Ordway J.M., McCombie W.R., Leon J., Jeddeloh J.A., McPherson J.D. Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. Genome Res. 2008, 18:19-29.
62. Kreso A., O'Brien C.A., van Galen P., Gan O.I., Notta F., Brown A.M., Ng K., Ma J., Wienholds E., Dunant C., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339:543-548.
63. Kulis M., Heath S., Bibikova M., Queiros A.C., Navarro A., Clot G., Martinez-Trillos A., Castellano G., Brun-Heath I., Pinyol M., et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 2012, 44:1236-1242.
64. Kulis M., Merkel A., Heath S., Queiros A.C., Schuyler R.P., Castellano G., Beekman R., Raineri E., Esteve A., Clot G., et al. Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nat. Genet. 2015, 47:746-756.
65. Landan G., Cohen N.M., Mukamel Z., Bar A., Molchadsky A., Brosh R., Horn-Saban S., Zalcenstein D.A., Goldfinger N., Zundelevich A., et al. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat. Genet. 2012, 44:1207-1214.
66. Landau D.A., Carter S.L., Stojanov P., McKenna A., Stevenson K., Lawrence M.S., Sougnez C., Stewart C., Sivachenko A., Wang L., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152:714-726.
67. Landau D.A., Clement K., Ziller M.J., Boyle P., Fan J., Gu H., Stevenson K., Sougnez C., Wang L., Li S., et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 2014, 26:813-825.
68. Lee M.C., Lopez-Diaz F.J., Khan S.Y., Tariq M.A., Dayn Y., Vaske C.J., Radenbaugh A.J., Kim H.J., Emerson B.M., Pourmand N. Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc. Natl. Acad. Sci. USA 2014, 111:E4726-E4735.
69. Li Y., Xu X., Song L., Hou Y., Li Z., Tsang S., Li F., Im K.M., Wu K., Wu H., et al. Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. Gigascience 2012, 1:12.
70. Lin P.C., Giannopoulou E.G., Park K., Mosquera J.M., Sboner A., Tewari A.K., Garraway L.A., Beltran H., Rubin M.A., Elemento O. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia 2013, 15:373-383.
71. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., Nery J.R., Lee L., Ye Z., Ngo Q.M., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462:315-322.
72. Lowdon R.F., Zhang B., Bilenky M., Mauro T., Li D., Gascard P., Sigaroudinia M., Farnham P.J., Bastian B.C., Tlsty T.D., et al. Regulatory network decoded from epigenomes of surface ectoderm-derived cell types. Nat. Commun. 2014, 5:5442.
73. Lui J.H., Nowakowski T.J., Pollen A.A., Javaherian A., Kriegstein A.R., Oldham M.C. Radial glia require PDGFD-PDGFRbeta signalling in human but not mouse neocortex. Nature 2014, 515:264-268.
74. Mack S.C., Hubert C.G., Miller T.E., Taylor M.D., Rich J.N. An epigenetic gateway to brain tumor cell identity. Nat. Neurosci. 2015, 19:10-19.
75. Maley C.C., Galipeau P.C., Li X., Sanchez C.A., Paulson T.G., Reid B.J. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 2004, 64:3414-3427.
76. Maley C.C., Galipeau P.C., Finley J.C., Wongsurawat V.J., Li X., Sanchez C.A., Paulson T.G., Blount P.L., Risques R.A., Rabinovitch P.S., Reid B.J. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 2006, 38:468-473.
77. Matei D.E., Nephew K.P. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol. Oncol. 2010, 116:195-201.
78. Mazor T., Pankov A., Johnson B.E., Hong C., Hamilton E.G., Bell R.J.A., Smirnov I.V., Reis G.F., Phillips J.J., Barnes M.J., et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 2015, 28:307-317.
79. McGregor K., Bernatsky S., Colmegna I., Hudson M., Pastinen T., Labbe A., Greenwood C. An evaluation of methods correcting for cell type heterogeneity in DNA methylation studies. bioRxiv 2015, 10.1101/032185.
80. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1995, 1:686-692.
81. Merlo L.M., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 2006, 6:924-935.
82. Merlo L.M.F., Shah N.A., Li X., Blount P.L., Vaughan T.L., Reid B.J., Maley C.C. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. (Phila) 2010, 3:1388-1397.
83. Mikeska T., Bock C., El-Maarri O., Hubner A., Ehrentraut D., Schramm J., Felsberg J., Kahl P., Buttner R., Pietsch T., Waha A. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J. Mol. Diagn. 2007, 9:368-381.
84. Min J.W., Kim W.J., Han J.A., Jung Y.J., Kim K.T., Park W.Y., Lee H.O., Choi S.S. Identification of distinct tumor subpopulations in lung adenocarcinoma via single-cell RNA-seq. PLoS One 2015, 10:e0135817.
85. Moelans C.B., de Groot J.S., Pan X., van der Wall E., van Diest P.J. Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA. Mod. Pathol. 2014, 27:869-874.
86. Myöhänen S.K., Baylin S.B., Herman J.G. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 1998, 58:591-593.
87. Nakamura M., Watanabe T., Klangby U., Asker C., Wiman K., Yonekawa Y., Kleihues P., Ohgaki H. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol. 2001, 11:159-168.
88. Nakamura M., Yonekawa Y., Kleihues P., Ohgaki H. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest. 2001, 81:77-82.
89. Nathanson D.A., Gini B., Mottahedeh J., Visnyei K., Koga T., Gomez G., Eskin A., Hwang K., Wang J., Masui K., et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 2014, 343:72-76.
90. Navin N., Kendall J., Troge J., Andrews P., Rodgers L., McIndoo J., Cook K., Stepansky A., Levy D., Esposito D., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
91. Nik-Zainal S., Van Loo P., Wedge D.C., Alexandrov L.B., Greenman C.D., Lau K.W., Raine K., Jones D., Marshall J., Ramakrishna M., et al. The life history of 21 breast cancers. Cell 2012, 149:994-1007.
92. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
93. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
94. Oakes C.C., Claus R., Gu L., Assenov Y., Hullein J., Zucknick M., Bieg M., Brocks D., Bogatyrova O., Schmidt C.R., et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2013, 4:348-361.
95. Oakes C.C., Seifert M., Assenov Y., Gu L., Przekopowitz M., Ruppert A.S., Wang Q., Imbusch C.D., Serva A., Koser S.D., et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat. Genet. 2016, 48:253-264.
96. Okosun J., Bodor C., Wang J., Araf S., Yang C.Y., Pan C., Boller S., Cittaro D., Bozek M., Iqbal S., et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 2014, 46:176-181.
97. Pan H., Jiang Y., Boi M., Tabbo F., Redmond D., Nie K., Ladetto M., Chiappella A., Cerchietti L., Shaknovich R., et al. Epigenomic evolution in diffuse large B-cell lymphomas. Nat. Commun. 2015, 6:6921.
98. Patel A.P., Tirosh I., Trombetta J.J., Shalek A.K., Gillespie S.M., Wakimoto H., Cahill D.P., Nahed B.V., Curry W.T., Martuza R.L., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014, 344:1396-1401.
99. Pieper R.O., Costello J.F., Kroes R.A., Futscher B.W., Marathi U., Erickson L.C. Direct correlation between methylation status and expression of the human O-6-methylguanine DNA methyltransferase gene. Cancer Commun. 1991, 3:241-253.
100. Portela A., Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28:1057-1068.
101. Rodriguez-Canales J., Hanson J.C., Tangrea M.A., Erickson H.S., Albert P.S., Wallis B.S., Richardson A.M., Pinto P.A., Linehan W.M., Gillespie J.W., et al. Identification of a unique epigenetic sub-microenvironment in prostate cancer. J. Pathol. 2007, 211:410-419.
102. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17:330-339.
103. Rotem A., Ram O., Shoresh N., Sperling R.A., Goren A., Weitz D.A., Bernstein B.E. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. Nat. Biotechnol. 2015, 33:1165-1172.
104. Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., Dryja T.P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet. 1991, 48:880-888.
105. Schonberg D.L., Lubelski D., Miller T.E., Rich J.N. Brain tumor stem cells: molecular characteristics and their impact on therapy. Mol. Aspects Med. 2014, 39:82-101.
106. Schramm A., Köster J., Assenov Y., Althoff K., Peifer M., Mahlow E., Odersky A., Beisser D., Ernst C., Henssen A.G., et al. Mutational dynamics between primary and relapse neuroblastomas. Nat. Genet. 2015, 47:872-877.
107. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., Turashvili G., Ding J., Tse K., Haffari G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
108. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
109. Shen H., Laird P.W. Interplay between the cancer genome and epigenome. Cell 2013, 153:38-55.
110. Siegmund K.D., Marjoram P., Woo Y.J., Tavare S., Shibata D. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc. Natl. Acad. Sci. USA 2009, 106:4828-4833.
111. Siegmund K.D., Marjoram P., Tavare S., Shibata D. High DNA methylation pattern intratumoral diversity implies weak selection in many human colorectal cancers. PLoS One 2011, 6:e21657.
112. Smallwood S.A., Lee H.J., Angermueller C., Krueger F., Saadeh H., Peat J., Andrews S.R., Stegle O., Reik W., Kelsey G. Single-cell genome-wide bisulfite sequencing for assessing epigenetic heterogeneity. Nat. Methods 2014, 11:817-820.
113. Snuderl M., Fazlollahi L., Le L.P., Nitta M., Zhelyazkova B.H., Davidson C.J., Akhavanfard S., Cahill D.P., Aldape K.D., Betensky R.A., et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20:810-817.
114. Sottoriva A., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavare S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 2013, 110:4009-4014.
115. Sottoriva A., Spiteri I., Shibata D., Curtis C., Tavare S. Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization. Cancer Res. 2013, 73:41-49.
116. Stirzaker C., Millar D.S., Paul C.L., Warnecke P.M., Harrison J., Vincent P.C., Frommer M., Clark S.J. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res. 1997, 57:2229-2237.
117. Strauss J., Figg W.D. Using epigenetic therapy to overcome chemotherapy resistance. Anticancer Res. 2016, 36:1-4.
118. Suzuki H., Aoki K., Chiba K., Sato Y., Shiozawa Y., Shiraishi Y., Shimamura T., Niida A., Motomura K., Ohka F., et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 2015, 47:458-468.
119. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
120. van Thuijl H.F., Mazor T., Johnson B.E., Fouse S.D., Aihara K., Hong C., Malmstrom A., Hallbeck M., Heimans J.J., et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015, 129:597-607.
121. Varley K.E., Mutch D.G., Edmonston T.B., Goodfellow P.J., Mitra R.D. Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acids Res. 2009, 37:4603-4612.
122. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
123. Vlassenbroeck I., Califice S., Diserens A.C., Migliavacca E., Straub J., Di Stefano I., Moreau F., Hamou M.F., Renard I., Delorenzi M., et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J. Mol. Diagn. 2008, 10:332-337.
124. Voet T., Kumar P., Van Loo P., Cooke S.L., Marshall J., Lin M.L., Zamani Esteki M., Van der Aa N., Mateiu L., McBride D.J., et al. Single-cell paired-end genome sequencing reveals structural variation per cell cycle. Nucleic Acids Res. 2013, 41:6119-6138.
125. Walter M.J., Shen D., Ding L., Shao J., Koboldt D.C., Chen K., Larson D.E., McLellan M.D., Dooling D., Abbott R., et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 2012, 366:1090-1098.
126. Wang Y., Waters J., Leung M.L., Unruh A., Roh W., Shi X., Chen K., Scheet P., Vattathil S., Liang H., et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014, 512:155-160.
127. Watanabe T., Nakamura M., Yonekawa Y., Kleihues P., Ohgaki H. Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol. 2001, 101:185-189.
128. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., Kang G.H., Widschwendter M., Weener D., Buchanan D., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006, 38:787-793.
129. Xu X., Hou Y., Yin X., Bao L., Tang A., Song L., Li F., Tsang S., Wu K., Wu H., et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012, 148:886-895.
130. Yadav V.K., De S. An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. Brief Bioinform. 2015, 16:232-241.
131. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5:37-50.
132. Yoshihara K., Shahmoradgoli M., Martinez E., Vegesna R., Kim H., Torres-Garcia W., Trevino V., Shen H., Laird P.W., Levine D.A., et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013, 4:2612.